Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 847-858

  Morra, R ^a,b   Munteanu, M ^b   Bedossa, P ^a,c   Dargere, D ^a   Janneau, J L ^a   Paradis, V ^a,c   Ratziu, V ^a,d   Charlotte, F ^e   Thibault, V ^e   Imbert Bismut, F ^e   Poynard, T ^a,d  

^a CNRS   (France)

^b Biopredictive   (France)

^c BEAUJON HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e GHPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34548309212     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03427.x     Document Type: Article

References (38)

1. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 32 : 477 81.
2. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986 1 : 523 5.
3. Ratziu V, Charlotte F, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005 128 : 1898 906.
4. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 8.
5. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
6. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006 44 : 686 93.
7. Haute Autorité de Santé Française. Avis HAS tests non invasifs mesure fibrose cirrhose. Available at: http://www.hassante.fr/ portail/display.jsp?id=c_476401 (last accessed July 18, 2007).
8. Munteanu M, Ratziu V, Imbert-Bismut F, Castille JM, Faruki H, Poynard T. Precautions of use of non-invasive biochemical markers of liver injury Fibrotest- Actitest-HCV FIBROSURE™ (FT-AT) in 32,527 patients with chronic hepatitis C. Hepatology 2004 40 : 686A (Abstract).
9. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 50 : 1344 55.
10. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005 51 : 328 35.
11. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005 42 : 665 74.
12. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005 41 : 40 7.
13. Dev A, Zekry A, Shaw L, Heller K, Patel K, McHutchison J. Independent evaluation of a serum biochemical marker panel (FibroTest) to predict fibrosis in a US cohort of chronic hepatitis C (CHC) patients. Hepatology 2004 40 : 686A (Abstract)
14. Gourley G, Yang L, David L, Corless C, Wertheimer A, Rosen H. Proteomics to predict hepatitis C Fibrosis. Hepatology 2003 38 : 442A (Abstract)
15. He QY, Lau GK, Zhou Y, et al. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 2003 3 : 666 74.
16. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004 96 : 353 6.
17. Hong H, Dragan Y, Epstein J, et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 2005 6 : S5.
18. Bons JAP, De Boer D, Van Dieijen-Visser MP, Wodzig WKWH. Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. Clin Chim Acta 2006 366 : 249 56.
19. Poynard P, Halfon P, Castera L, et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007 25 : 733 39.
20. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004 42 : 323 33.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 : 837 45.
22. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York : John Wiley & Sons, 2002.
23. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002 36 : S161 72.
24. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007 13 : 525 31.
25. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines J Hepatol 2007 46 : 528 9.
26. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics Clin Chem 2003 49 : 1272 5.
27. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 75.
28. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004 3 : 8.
29. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterol 2006 101 : 547 55.
30. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006 52 : 1887 96.
31. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004 10 : 1 6.
32. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol 2004 10 : 2327 9.
33. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002 9 : 128 33.
34. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007 46 : 395 402.
35. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005 100 : 1970 80.
36. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003 39 : 222 30.
37. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006 6 : 6.
38. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005 3 : 167 74.